Stoke Therapeutics, Inc. (STOK)

Market Cap	606.24M
Revenue (ttm)	8.78M
Net Income (ttm)	-104.70M
Shares Out	51.86M
EPS (ttm)	-2.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	507,869
Open	11.41
Previous Close	11.66
Day's Range	11.11 - 11.82
52-Week Range	3.35 - 16.40
Beta	0.76
Analysts	Strong Buy
Price Target	20.43 (+74.77%)
Earnings Date	May 6, 2024

About STOK

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2019
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: STOK

Financial Performance

In 2023, STOK's revenue was $8.78 million, a decrease of -29.22% compared to the previous year's $12.41 million. Losses were -$104.70 million, 3.59% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price forecast is $20.43, which is an increase of 74.77% from the latest price.

Price Target

$20.43

(74.77% upside)

Analyst Consensus: Strong Buy